PF-07832837

Phase 1Small molecule

Pfizer

PF-07832837 is one of 43 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisRecruiting

Atopic DermatitisPhase 1

Recruiting

Competition

Competitive Landscape

116 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

1 2

Fludara

Sanofi

Phase 3

1 3

Adtralza

LEO Pharma

Phase 3

17 4

Amlitelimab

Sanofi

Phase 3

2 5

DUPIXENT

Regeneron

Phase 3

1 6

Certolizumab

Johnson & Johnson

Phase 3

1 7

ICP-332

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

2 8

VC005

JJiangsu vcare pharmaceutical technology co., LTD

Phase 3

5 9

MG-K10

SShanghai Mabgeek Biotech.Co.Ltd

Phase 3

2 10

LNK01001

LLynk Pharmaceuticals Co., Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Atopic Dermatitis

NCT06564389

Clinical

Trials by Indication[1]

Atopic Dermatitis1 trial

A PHASE 1, FIRST IN HUMAN, RANDOMIZED, DOUBLE-BLIND, SPONSOROPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07832837 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT06564389·119 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PF-07832837. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-07832837 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-07832837. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Pfizer

PF-07832837

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News